This is a time sensitive test. Ideally testing needs to commence within 24 hours of collection. Weekend collections will be performed urgently on the following Monday.
This test is medicare rebatable
APPLICATION: This test detects the abnormal fusion gene (BCR-ABL) diagnostic of chronic myeloid leukaemia (CML) and some case of acute leukemia. The test is performed at diagnosis to identify these forms of leukemia (or rule it out). The test is used ongoing after diagnosis to assess treatment response. The drugs used to treat BCR-ABL positive leukemias specifically target the BCR-ABL gene. Treatment success is indicated by a fall in BCR-ABL levels over time. Treatment failure or relapse is indicated by a rise in BCR-ABL levels.